Determining The Role of MicroRNAs in Self-Renewal, Metastasis and Resistance to Drugs in Human Gastric Cancer Based on Data Mining Approaches: A Systematic Review.
Drug Resistance
Gastric Cancer
Metastasis
MicroRNA
Stem Cells
Journal
Cell journal
ISSN: 2228-5806
Titre abrégé: Cell J
Pays: Iran
ID NLM: 101566618
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
09
12
2019
accepted:
09
05
2020
entrez:
19
2
2022
pubmed:
20
2
2022
medline:
20
2
2022
Statut:
ppublish
Résumé
Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. The major problems of patients with GC are the lack of proper response to the treatment, drug resistance and metastasis attributed to the presence of a subpopulation of cells inside the tumour that are called cancer stem cells (CSCs). In addition, deregulation of microRNAs (miRNAs) has been reported in different stages of GC. The aim of the present study is to determine and introduce miRNAs that contribute to regulation of stemness, metastasis and drug resistance in GC. A systematic review, we conducted data mining of available datasets and a review of previous studies to select miRNAs that target stemness, epithelial-mesenchymal transition (EMT) and drug resistance. All selected miRNAs were analysed by R software to find a common miRNA target for all three processes. Then, the target prediction of miRNAs and their related signalling pathways were obtained by using bioinformatics tools, ONCO.IO and KEGG databases, respectively. We identified seven miRNAs (miR-34a, miR-23a, miR-27a, miR-30a, miR-19b, miR-107, miR-100) from our searching approach. These miRNAs regulate pathways that contribute to stemness, EMT and drug resistance in GC. Four (miR- 34a, miR-23a, miR-30a, and miR-100) had significant interactions with each other and 52 target genes among them, from which
Identifiants
pubmed: 35182058
doi: 10.22074/cellj.2022.7173
pmc: PMC8876259
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1-6Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
There is no conflict of interest in this study.
Références
Oncol Lett. 2016 Apr;11(4):2661-2667
pubmed: 27073535
Cancer Cell Int. 2019 Dec 27;19:354
pubmed: 31889906
Cell Death Dis. 2015 May 21;6:e1766
pubmed: 25996293
J Mol Med (Berl). 2014 Apr;92(4):321-36
pubmed: 24509937
Ann Transl Med. 2015 Dec;3(21):332
pubmed: 26734642
Tumour Biol. 2014 Oct;35(10):9801-6
pubmed: 24981249
Oncol Rep. 2019 Mar;41(3):1439-1454
pubmed: 30628706
Asian Pac J Cancer Prev. 2016;17(S3):27-32
pubmed: 27165203
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
Sci Rep. 2016 Feb 05;6:20502
pubmed: 26846307
Oncol Lett. 2018 Jan;15(1):453-458
pubmed: 29422961
Tumour Biol. 2014 Feb;35(2):1287-95
pubmed: 24068565
World J Gastroenterol. 2015 Nov 21;21(43):12261-73
pubmed: 26604635
Cancers (Basel). 2013 Jan 16;5(1):48-63
pubmed: 24216698
Nat Med. 2011 Feb;17(2):211-5
pubmed: 21240262
Biosci Biotechnol Biochem. 2017 Jan;81(1):119-126
pubmed: 27729002
Adv Drug Deliv Rev. 2015 Jan;81:94-103
pubmed: 25450261
Clin Exp Gastroenterol. 2020 Nov 05;13:511-542
pubmed: 33177859
Eur J Cancer. 2015 Dec;51(18):2820-32
pubmed: 26589974
BMC Cancer. 2008 Sep 21;8:266
pubmed: 18803879
Oncol Rep. 2019 Jan;41(1):87-102
pubmed: 30320349
Cell Physiol Biochem. 2016;38(2):427-48
pubmed: 26828359
N Engl J Med. 2005 Oct 27;353(17):1768-71
pubmed: 16251533
Stem Cells Int. 2018 Feb 28;2018:5416923
pubmed: 29681949
Int J Clin Exp Med. 2015 Feb 15;8(2):2635-41
pubmed: 25932212
Med Sci Monit. 2016 Nov 23;0:0
pubmed: 27876712
J Clin Med. 2019 May 09;8(5):
pubmed: 31075910
Int J Clin Exp Pathol. 2014 Dec 01;7(12):8833-40
pubmed: 25674252
PLoS One. 2017 Feb 27;12(2):e0172791
pubmed: 28241049